[1]中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018,21(2): 177-186. [2]Ren TY, Fan JG. What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol, 2021,18(5):289-290. [3]Lee YH, Jung KS, Kim SU, et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol, 2015,63(2): 486-493. [4]Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011). Hepatology, 2016,63(3): 776-786. [5]Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol, 2017,66(1): 123-131. [6]潘勤, 范建高. 肠源性高血氨在非酒精性脂肪性肝炎发病中的作用. 实用肝脏病杂志, 2020,23(6): 761-764. [7]De Chiara F, Heebøll S, Marrone G, et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J Hepatol, 2018,69(4): 905-915. [8]Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol, 2016,65(6): 1232-1244. [9]Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing, 2019,48(4): 601. [10] 宋叶雨, 范建高. 少肌性肥胖合并脂肪性肝病的诊断与治疗. 实用肝脏病杂志, 2021,24(1): 149-152. [11] Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005,41(6): 1313-1321. [12] Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology, 2014,59(5): 1772-1778. [13] Bhanji RA, Narayanan P, Allen AM, et al. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology, 2017,66(6): 2055-2065. [14] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol, 2017,67(4): 862-873. [15] Kwon Y, Jeong SJ. Relative skeletal muscle mass is an important factor in non-alcoholic fatty liver disease in non-obese children and adolescents. J Clin Med, 2020,9(10): 3355. [16] 田丽艳, 陆伦根, 唐承薇, 等. 门冬氨酸-鸟氨酸颗粒剂治疗非酒精性脂肪性肝炎的多剂量平行对照临床研究. 中华肝脏病杂志, 2013,21(7): 528-532. [17] Butterworth RF, Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in non-alcoholic fatty liver disease. Dig Dis, 2019,37(1): 63-68. |